Yahoo
XETRA - Delayed Quote EUR

Fresenius SE & Co. KGaA (FRE.DE)

47.80 +0.79 (+1.69%)
At close: October 30 at 5:35:18 PM GMT+1
Chart Range Bar
Loading chart for FRE.DE
  • Previous Close 47.00
  • Open 47.40
  • Bid 47.65 x --
  • Ask 47.79 x --
  • Day's Range 47.23 - 47.92
  • 52 Week Range 35.11 - 52.96
  • Volume 747,588
  • Avg. Volume 964,736
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.82
  • PE Ratio (TTM) 17.25
  • EPS (TTM) 2.77
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 1.05 (2.20%)
  • Ex-Dividend Date May 25, 2026
  • 1y Target Est 56.41

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

www.fresenius.com

178,486

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

FRE.DE
0.30%
DAX P (^GDAXI)
5.42%

1-Year Return

FRE.DE
2.45%
DAX P (^GDAXI)
7.05%

3-Year Return

FRE.DE
107.13%
DAX P (^GDAXI)
75.44%

5-Year Return

FRE.DE
36.38%
DAX P (^GDAXI)
64.56%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 5.86B
Earnings 382M
Profit Margin 6.51%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
2B
4B
0.0%
2.0%
4.0%
6.0%

Analyst Insights

View More

Analyst Price Targets

52.00
56.41 Average
47.79 Current
64.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.54%

  • Return on Assets (ttm)

    3.43%

  • Return on Equity (ttm)

    8.29%

  • Revenue (ttm)

    23.28B

  • Net Income Avi to Common (ttm)

    1.56B

  • Diluted EPS (ttm)

    2.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.28B

  • Total Debt/Equity (mrq)

    55.98%

  • Levered Free Cash Flow (ttm)

    1.71B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: